Futscher B W, Abbaszadegan M R, Domann F, Dalton W S
Bone Marrow Transplant Program, Arizona Cancer Center, Tucson 85724.
Biochem Pharmacol. 1994 Apr 29;47(9):1601-6. doi: 10.1016/0006-2952(94)90538-x.
MRP, a gene recently isolated from a non-P-glycoprotein-mediated multidrug-resistant small cell lung cancer cell line, is a candidate multidrug-resistance gene. Mitoxantrone, an anthracenedione antitumor agent, frequently selects for non-P-glycoprotein-mediated multidrug resistance in in vitro models. To determine whether mitoxantrone-selected multidrug resistance was due to overexpression of MRP, we examined the expression of MRP in four mitoxantrone-selected, multidrug-resistant human tumor cell lines, using a reverse transcriptase/polymerase chain reaction assay. Results from these experiments suggest that overexpression of MRP does not appear to play a primary role in mitoxantrone-selected multidrug resistance in these cell lines, and that other novel drug-resistance mechanisms are likely.
MRP是最近从一个非P-糖蛋白介导的多药耐药小细胞肺癌细胞系中分离出来的基因,是一个多药耐药候选基因。米托蒽醌是一种蒽二酮类抗肿瘤药物,在体外模型中常导致非P-糖蛋白介导的多药耐药。为了确定米托蒽醌诱导的多药耐药是否是由于MRP的过表达,我们使用逆转录酶/聚合酶链反应分析法检测了四个经米托蒽醌诱导产生多药耐药的人肿瘤细胞系中MRP的表达。这些实验结果表明,MRP的过表达似乎在这些细胞系中米托蒽醌诱导的多药耐药中并不起主要作用,可能存在其他新的耐药机制。